Quick Answer
Apogee Therapeutics, Inc. reported Research And Development Expense of $214.71 million for the year ending 2025.
- Apogee Therapeutics, Inc. showed an increase of +27.9% in Research And Development Expense from 2024 to 2025.
- This data is from Apogee Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $1.45 million | Q3 2022: $9.89 million | Q1 2023: $8.46 million | Q2 2023: $13.95 million | Q3 2023: $17.07 million | Q1 2024: $28.72 million | Q2 2024: $33.21 million | Q3 2024: $45.71 million | Q1 2025: $46.39 million | Q2 2025: $55.70 million | Q3 2025: $54.18 million.
- Over the full 4 years of available data (2022 to 2025), Apogee Therapeutics, Inc.'s Research And Development Expense has grown by 672.7%.
- Historical annual values: Fiscal year 2025: $214.71 million | Fiscal year 2024: $167.87 million | Fiscal year 2023: $68.42 million | Fiscal year 2022: $27.79 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: